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SUMMARY. Hepatitis C virus (HCV) infection is gaining
increasing attention as a global health crisis. Egypt reports the
highest prevalence of HCV worldwide, ranging from 6% to
more than 40% among regions and demographic groups.
Predicting the impact of the epidemic has been difficult
because of the long-latency period and low-resource setting.
Accordingly, we sought to estimate historic incidence and
predict the future impact of HCV using Markov simulation
modelling techniques. Age-specific HCV incidence rates (IRs)
were estimated using previously acquired age-specific HCV
prevalence data. Data for this analysis were from a highly
detailed, community-based seroprevalence study from 2003.
Future HCV-related morbidity and mortality were estimated
using a computer cohort simulation of HCV natural history in
the Egyptian population. Population and natural history
parameters were defined using results from a meta-analysis
and existing comprehensive literature reviews. Incidence
model estimates ranged from 2.01 to 25.47 HCV cases per
1000 person-years (PYs). The highest IRs were calculated
among those over 35 years of age. Our Markov model pre-
dicted 127 821 deaths from chronic liver disease and
117 556 deaths from hepatocellular carcinoma in Egypt over
the next 20 years. During this period, it was estimated that
HCV would yield 750 210 PY of decompensated cirrhosis,
132 894 PY of hepatocellular carcinoma, and a total loss of
32.86 million years of life compared to a non-infected cohort.
Our results support the claim of high HCV incidence in Egypt
and suggest that HCV may lead to a substantial health and,
consequently, economic burden over the next 10–20 years.
Keywords: developing countries, indirect incidence, infec-
tious disease, liver cancer, Markov model.
INTRODUCTION
Hepatitis C virus (HCV) infection is gaining increasing
attention as a global health problem, with approximately 3%
of the worlds population infected [1,2]. These individuals
are at greater risk for developing cirrhosis and/or hepato-
cellular carcinoma (HCC). Egypt reports the highest preva-
lence of HCV worldwide, ranging from 6% to more than 40%
with an average of 13.8% [3–5]. In populations of blood
transfusion recipients over the age of 30, this proportion has
been reported to be as high as 73%, and in the general
population aged 40–60 years it can be as high as 55%. At
the same time, the prevalence in children is much lower,
ranging between 2% and 10% [3–5]. While the levels
in children are much lower than those seen in the older
population, they are still excessive by World Health
Organization (WHO) standards, where prevalences greater
than about 3–4% are considered high [2].
In Egypt, the major route of exposure to HCV appears to
have been via widespread parenteral antischistosomal
treatment (PAT), with more than 35 million injections given
over a 20-year period (1960–1980) [3]. Despite termination
of this program and the implementation of measures de-
signed to reduce hospital-related infection, transmission
continues.
Because the prevalence of HCV is exceeding that of HBV
infection, HCV infection has become the leading risk factor
for HCC in Egypt (antibodies present in as many as
75–90% of HCC cases) [6]. The frequency of liver-related
cancers (>95% as HCC) relative to all cancers in Egypt
has increased from approximately 4.0% in 1993 to 7.3%
in 2003 [7]. Now the second highest cause of cancer
incidence and mortality among men, HCC in Egypt occurs
at rates significantly greater than those seen in
surrounding Middle Eastern countries, as well as in the
USA [8].
Incidence data are limited, however, because researchers
have been plagued by logistical and methodological diffi-
culties. Initial infection is rarely symptomatic, and chronic
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carriage is insidious. Thus, it is important to characterize the
HCV situation in Egypt to predict the future health burden
and guide appropriate health policy to confront the issue.
Various mathematical techniques provide practical
approaches for making reasonable estimates about the his-
tory of the HCV epidemic and future predictions of HCV-
related morbidity and mortality. Methods for indirectly
calculating age-specific incidence rates (IRs) using seropre-
valence data were developed during the 1980s [9–11]. Saidel
et al. [12] successfully validated one of these methods for HIV
by comparing its predictions with observations from an
incidence study. Such a method is advantageous, as it uses
data from a single cross-sectional survey to estimate
incidence and is particularly appropriate for developing
countries where incidence data are frequently unavailable or
unreliable.
The purpose of this study was to provide quantitative
estimates of the burden of HCV infection among Egyptians.
Burden was measured in two ways: First, we examined the
burden of past infection incidence to further probe the
hypothesis that the PAT campaign was largely responsible
for the present epidemic in Egypt and shed light on the
resulting epidemic curve, applying indirect estimates of his-
torical IRs using seroprevalence data. Second, we used a
Markov natural history model to estimate the impact of this
epidemic, measured as future morbidity and mortality from
sequelae of chronic HCV infection.
MATERIAL AND METHODS
Prevalence and population data
Age- and sex-specific population and mortality data for
5-year age groups were obtained from Egypts Central
Agency for Public Mobilization and Statistics (CAPMAS) and
the WHO [13,14].
Prior systematic review of the literature identified high
quality HCV prevalence studies for the period 1992–2005
[15]. Briefly, we selected five studies from the period 2001–
2002, which we considered to have the greatest amount of
detail and the highest methodological quality [4,16–19]. All
studies were conducted on large (n > 1400) apparently
healthy community-based populations. Third generation
ELISA was used in all cases to test for HCV antibody. These
studies covered ages 5–60+ years as well as geographic re-
gions of interest (Upper and Lower Egypt). Since it is known
that prevalence varies significantly between children and
adults as well as between Upper and Lower Egypt, this
sample of studies is highly representative of Egypt when
considered in aggregate.
Age-specific prevalences across studies were compared
using the chi-square test to determine if pooling results would
be appropriate. No significant differences were found among
adults from Lower Egypt, children from Lower Egypt, adults
from Upper Egypt, or children from Upper Egypt. Summary
age-specific prevalence measures, as well as male:female
ratios from these studies, were calculated as weighted
averages using a standard method [20]. The individual
prevalence for each study was multiplied by the corre-
sponding sample size and divided by the total (pooled) sample
size of all studies. To populate the initial values of the HCV
Infection health state in the Markov model, these summary
age-specific prevalence proportions (adjusted for sex) were
multiplied by their respective census population values.
Incidence rate estimates
The method for estimating age-specific IRs from prevalence
data was originally described by Leske et al. [9], Podgor et al.
[10] and Podgor and Leske [11]. Although initially devel-
oped for studying glaucoma, Saidel et al. [12] tested model
predictions against observed incidence for HIV/AIDS and
determined the model can provide crude estimates of 1-year
age-specific IRs that are similar to those observed in longi-
tudinal studies of HIV/AIDS. For these calculations, we chose
to select only one of the studies mentioned above, so as not
to introduce bias. Since we are inferring incidence measures,
it is best not to pool studies where HCV seroprevalence was
measured by different researchers on different populations.
This decision was made in the interest of preserving internal
validity at the expense of external validity and the ability to
generalize results beyond the specific study population of
interest. We chose to focus our investigation of incidence on
the data from Arafa et al. [18], which presents age-specific
prevalence from an area in Lower Egypt, the region known
to have higher levels of HCV in Egypt [17].
Incidence rates are derived by using estimated prevalence
of disease at the beginning and end of an age interval and
the known age-specific mortality rates during the interval.
The model is based on the functional relation between a risk
(CI) and a rate (ID) as:
CI ¼ 1 eðIDDtÞ
where ID is incidence density, CI is cumulative incidence,
and Dt is the elapsed time (which could be defined by age
differences), as long as the assumption of constant incidence
within a time interval is not violated [12]. After accounting




lnð1 qxÞ þ lnð1PxÞ
 1 ð1PxÞð1 qxÞð1 1=2qxÞ
where Ix is the incidence rate for the age interval; qx the
probability of dying during the age interval; x + 1 = age




where Px is the prevalence proportion at the beginning of the
interval.
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After solving for Ix, it is divided by the number of years in
the age interval to estimate the mean annual rate for time
interval x. In 1983, Podgor et al. validated this model
against other, more established methods [10]. For more de-
tails on the derivation and validation of this method, see
Refs. [9–12]. Variance and standard error for model esti-
mates were calculated using the delta method described by
Armitage and Leske [9,21], respectively, as:
VarðIxÞ ¼ ½@Ix=@Px2VarðPxÞ
To use this model, it is necessary to address the following
three assumptions:
1. Infection is lifelong and irreversible. We limit our analysis to
chronically infected individuals, as the rate of remission is
quite low. In addition, treatment for HCV in Egypt is
limited and rarely successful in eliminating infection.
2. Homogeneity within age intervals. This model assumes
mortality rates, disease IRs and population risk factors
remain constant within the age intervals of analysis.
We restricted age intervals to 5-year periods, making
it reasonable to assume homogeneity of these
characteristics within age categories.
3. Non-differential mortality rates between HCV+ and HCV–
individuals. Model estimates using this method are not
robust when one age interval is followed by another with
lower prevalence (results in a negative incidence) [12].
For the purpose of this analysis, therefore, age groups
>50-years old (yo) were excluded, because prevalence
levels begin to decline. Truncating this analysis to those
<50 yo is reasonable, since the purpose is to identify
recent incidence trends following the elimination of the
PAT campaign, making younger age groups more rele-
vant. Adjusting for differential mortality due to cirrhosis/
liver failure/HCC would be essential in populations
>50 yo, but it is negligible in younger groups. Differential
mortality is the result of long-term sequelae associated
with chronic HCV infection. Previous work has shown
that these sequelae have their greatest impact in the
population over 50 yo and have little effect in younger
individuals [6–8,22]. However, access to cirrhosis and
other non-HCC liver disease mortality data was extremely
limited despite extensive searching. In our own sensitivity
analyses, we found the estimates to be fairly stable in the
presence of varying mortality rates. Thus, because we
limited age groups to <50 yo, no adjustment for differ-
ential mortality was needed.
Future HCV-related morbidity/mortality
Using Visual Basic for Microsoft Excel, we developed a
Markov simulation model to predict HCV-related morbidity
and mortality among a cohort representative of the HCV-
infected population in Egypt (Fig. 1; Table 1). Cohort mem-
bers move among health states over 1-year time steps for
20 years. By tracking the proportion of the cohort develop-
ing sequelae, we were able to estimate the future health
burden. The likelihood of health state transitions was based
on probabilities derived from a review of the literature as
well as publications from the WHO Hepatitis C Working
Group (Table 1; the literature used to guide parameter esti-
mates is cited in Appendix 1). The initial HCV Infection
Health state was populated using the summary age-specific
prevalence proportions discussed above and multiplying
them by their respective census population estimates.
The model is set up to include ages 0–80 (time
step = 1 year). Anyone alive at age 80 years dies by age 81.
Since life expectancy in Egypt is 69 for males and 73 for
females, and the population over 80 years of age accounts
for only 0.3% of the total population, this age structure
seems reasonable [14]. To incorporate aging into the model,
we added the probability of remaining in a healthy
state from one time step to the next, which is simply
[1 – sum(transition probabilities to different health states)].
This exists for all health states except the original HCV
infection. No one remains in the HCV infection health state
after the first time step, when people are either moved to
chronic infection, or removed from the system in the reso-
lution health state.
Age- and sex-specific background mortality rates were
obtained from the WHO and are applied to the following
health states: chronic HCV infection, compensated cirrhosis,
and decompensated cirrhosis [14]. All deaths from hepato-
cellular carcinoma are considered to be attributed to it. No
deaths occur in the first time step. Typically, hepatitis C
infection resolves or becomes chronic within the first year of
infection [1,2]. Since our prevalence estimates are popula-
tion-based, the first time step is designed to appropriately
calculate the number of chronically infected individuals.
Sex is incorporated only insofar as generating the initial
population structure and applying age-sex-specific back-
ground mortality. Although we hypothesize that transition
probabilities may indeed be different by sex, they have yet
to be clearly defined in the literature and from prospective
cohort studies. Since previous research has indicated a
HCV infection
Death
C. CirrhosisChronic HCV D. Cirrhosis
HCCResolution
Background mortality
Fig. 1 Natural history model for Hepatitis C virus infection
and its sequelae. Conceptual model showing the health
states incorporated into the Markov simulation model. C,
compensated; D = decompensated.
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greater proportion of males are infected in Egypt vs females,
sex is included to reflect these different initial values [3–
7,16-19]. For the Markov model alone, it provides little be-
yond the initial values and the ability to project sex-specific
health outcomes.
The disability or mortality burdens related to HCV infec-
tion were estimated. We used the computer simulation to
determine the years of life spent by the cohort with de-
compensated cirrhosis or hepatocellular carcinoma (HCC).
To estimate the years of life lost, we also compared life
expectancy estimates for the chronic HCV population with
those for an age- and sex-matched general population.
These estimates calculated premature mortality and
assumed permanent disability once patients developed
decompensated cirrhosis or HCC, but did not consider
quality-of-life deficits, as no such studies have been reported
from Egypt that would provide appropriate quality of life
information for HCV infection. The model was limited to
20 years because: (1) the natural history beyond 20 years is
less certain, weakening our confidence in parameter esti-
mates; and (2) estimates of disease and death are less
meaningful, as they would not include incident cases who
became infected during the period of analysis (due to the
unavailability of incidence data).
RESULTS
Age-specific prevalence
All studies used in calculating summary measures had
sample sizes greater than 1400, reducing the probability of
bias in prevalence estimates due to low power. Chi-square
tests revealed no significant differences between studies
measuring redundant populations (i.e. adults from Lower
Egypt), so summary measures for the natural history model
were calculated (not shown).
Summary prevalence estimates were calculated for the
following age groups: 5–9, 10–14, 15–19, 20–29, 30–39,
40–49, and 50+. As expected, prevalence consistently in-
creased with age except for a decrease between the age
groups 40–49 and 50+. The decrease in the final age group
could be related to lower past exposure to HCV through PAT
which is tightly linked to HCV infection. Pooled estimates
also revealed a male:female ratio of 1.2:1 for ages
0–19 years and 1.6:1 for individuals ‡20.
Incidence rate estimates
Raw prevalence measures used in the calculation of
IRs [18] were smoothed by fitting them to a logistic curve
(1/e(a – bx)), where a = )4.172 and b = )0.076 (Fig. 2).
Table 2 presents the results from the age-specific IR calcu-
lations. Mean annual IRs were obtained by dividing the
model estimate by the number of years included in the age
interval (5 years). Model estimates ranged from 2.01 to
25.47 per 1000 PY. The highest IRs were calculated for
those ‡35 yo. Such high incidence for these people is con-
sistent with the age cohort effect seen with respect to the
PAT campaign. We were unable to estimate the IRs for
those ‡50 yo, because prevalence significantly decreases
beginning with the 55–59 yo age group. This particular
method for estimating incidence loses accuracy under these
conditions and frequently results in the calculation of a
negative IR.
Table 1 Health state transition probability estimates used in the Markov simulation





HCV infection Chronic infection 0.75 0.50 0.85
Infection resolution 1-P(Chronic)
Chronic infection Compensated cirrhosis* 0.05/20 (<40 years) N/A N/A
Background mortality 0.20/20 (40+ years)
Compensated cirrhosis Decompensated cirrhosis
Hepatocellular carcinoma 0.065 0.04 0.092
Background mortality 0.035 0.024 0.046
Decompensated cirrhosis Death from D cirrhosis
Background mortality 0.186 0.137 0.300
Hepatocellular carcinoma Death from HCC 0.95
Upper and lower bound estimates for sensitivity analysis were determined based on error associated with parameter estimates
found in the literature.
*The compensated cirrhosis transition probability is 0.05 over 20 years if the individual was initially infected with HCV prior to
40 years of age. The transition probability is 0.2 over 20 years if the individual was aged 40 years or older at the time of initial
HCV infection (Appendix 1). Background mortality is defined by age-sex-specific rates obtained from WHO [14]. All death
from hepatocellular carcinoma is assumed to be attributed to it.
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Future HCV-related morbidity and mortality
Predictions from the Markov model that estimate future
HCV-related morbidity and mortality in Egypt, including the
upper and lower bound estimates from sensitivity analysis,
are striking (Table 3). Based on review of the prevalence
studies, approximately 8.84 million individuals (4.98 million
males and 3.86 million females) are estimated to be infected
with HCV in Egypt, resulting in 6.62 million with chronic
infection. Our model predicted that over the next 20 years a
total of 127 821 deaths due to decompensated cirrhosis
would occur in this cohort, plus another 117 556 deaths
due to HCC. The highest proportion of deaths related to HCV
will occur 10–20 years from now. Deaths due to HCC appear
to peak within 15–16 years, whereas deaths due to
decompensated cirrhosis only begin to flatten out in the final
2 years of analysis (Fig. 3). Deaths from HCC are greater
than deaths from decompensated cirrhosis earlier in the
model, due to the fact that individuals diagnosed with HCC
in Egypt typically do not live past 1 or 2 years, whereas
people with decompensated cirrhosis can live several years
before succumbing to the condition.
In addition to the 244 377 HCV-related deaths predicted
by the model, when compared with an age-matched general
population over the same time period, the HCV-infected
cohort would have accumulated 3 862 643 years of
compensated cirrhosis, 750 210 years of decompensated
cirrhosis, 132 894 years of hepatocellular carcinoma, and
the loss of 32.86 million years of life.
DISCUSSION
The objective of this study was to estimate past incidence of
HCV using an indirect method and make projections about
the future health burden using a natural history model.
Despite Egypts status as the country with the highest levels
of HCV infection in the world, few studies have been done to
characterize the dynamics of transmission, how they may
have changed over time, and what this means for the future
of health in Egypt. There is little doubt that the HCV
epidemic is largely the result of some health care workers
using unsterilized needles during the PAT campaign
between the 1960s and the 1980s [3,6,23,24]. Beyond
identifying PAT as the dominant source of infection, how-
ever, little research has been undertaken to characterize




























Fig. 2 Raw age-specific HCV prevalence proportions
in Lower Egypt, 2002. Data from Arafa et al. [18] were
used and plotted with smoothed age-specific prevalence
estimates. Prevalence data were fit to a logistic curve:
1/e(–a – bx) where a = )4.172; b = )0.076.
Table 2. Indirectly estimated age-










5–9 1.0 2.2 0.010 (0.01) 2.01
10–14 3.0 3.2 0.014 (0.01) 2.89
15–19 5.0 4.6 0.021 (0.01) 4.13
20–24 7.5 6.5 0.029 (0.01) 5.85
25–29 7.5 9.3 0.041 (0.03) 8.19
30–34 12.5 13.0 0.056 (0.03) 11.28
35–39 22.0 17.9 0.076 (0.04) 15.21
40–44 33.0 24.1 0.010 (0.05) 19.99
45–49 35.5 31.7 0.127 (0.06) 25.47
50–54 40.5 40.4 – –
55–59* 32.0 49.8 – –
60+* 22.5 59.1 – –
Incidence rates were calculated using smoothed age-specific prevalence measures.
Data were fit to a logistic curve: 1/e(a – bx) where a = )4.172; b = )0.076.*Not
included in incidence calculations to preserve integrity of the smoothed prevalence
estimates.
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studies show a significantly lower level of HCV infection
among younger individuals, with rural populations
approximately 12% and urban areas at only 2–3% [3,4,16–
19]. This still exceeds the WHOs definition of high ende-
micity (4%), leaving Egypts position as a leading country in
the burden of HCV unchanged. Recent cross-sectional
studies have found little evidence that formal medical pro-
cedures still contribute to transmission. In addition, informal
medical procedures, such as circumcision performed by a
barber, show significant associations but can only explain
between 10% and 20% of the infections [3,4,6]. Some have
suggested that intra-familial transmission may be crucial in
transmission, but this hypothesis has yet to be specifically
tested [25–27]. Although illuminating, such reports do not
help with inferences regarding the future of HCV, and con-
sequently the future of liver disease, in Egypt.
Incidence estimates
To address this knowledge gap, we calculated past age-spe-
cific HCV IRs using a method that analyses HCV prevalence
data from a one-time, cross-sectional survey. Although
originally developed for studying chronic diseases like glau-
coma, Saidel et al. [12] demonstrated the validity of this
method when compared with observational data from a
HIV/AIDS study. As expected, we identified very high IRs
among those ‡30 yo. Among those <30 yo, largely com-
prised of people unaffected by the PAT campaign, we noted a
continuous decline in IRs. Despite lower incidence among
those 5–14 yo, IRs remained at 2–3 per 1000 PY, suggest-
ing that transmission to children must still be occurring
despite the elimination of PAT and intense measures to re-
duce other iatrogenic exposures. Future longitudinal studies
are needed to gather observational data both to validate
these findings as well as to test hypotheses regarding the
current dominating modes of transmission.
We recognize that incidence estimates are only as valid as
the model assumptions are robust. One important limitation
of the model is the assumption of constant IRs [9–12]. The
degree to which violation of this assumption may have
affected model estimates is unpredictable and difficult to
assess. We were unable to acquire prevalence data for age
intervals of <5 years. Perhaps constancy was absent in some
of these age groups, but the natural history of HCV, as well
as the strong influence of widespread PAT and iatrogenic
exposures, suggest that 5-year-age intervals were reason-
able. Since the primary modes of transmission among
younger people have yet to be clearly identified, the proba-
bility of violating the constant incidence assumption is likely
greater, but 5-year intervals seem to be appropriate resolu-
tion for examining incidence among younger populations.
Furthermore, because HCV has high prevalence in Egypt, the
composition of risk groups is likely to change as the
population at risk becomes saturated with infection. The
steady-state condition assumed by the model may not have
been fully met, suggesting that the relation between
prevalence, incidence, and duration will only produce rough
estimates [12].
The Podgor and Leske-based method can result in nega-
tive estimates of the IRs if prevalence at an older age is
sharply less than at an earlier age [9,12]. Such estimates
obviously are invalid, indicating either: (1) lack of power
and/or too much variability among age groups, or (2) the
model assumptions do not hold in the age range being
examined. Therefore, we were unable to obtain incidence
Table 3 Predicted HCV-related morbid-
ity and mortality Health state Estimate Lower bound Upper bound
Compensated cirrhosis (life years) 3 862 643 2 902 917 3 881 476
Decompensated cirrhosis (life years) 750 210 392 042 818 895
Hepatocellular carcinoma (life years) 132 894 68 132 176 333
Decompensated cirrhosis (deaths) 127 821 48 728 227 701
Hepatocellular carcinoma (deaths) 117 556 59 960 156 713
Estimates were measured as life years or number of deaths. Upper and lower
bound estimates were obtained by varying parameter estimates in accordance




















Fig. 3 Future HCV-related morbidity and mortality in
Egypt. Predicted mortality due to HCV-related decompen-
sated cirrhosis and hepatocellular carcinoma over a 20-year
period.
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estimates for age groups >50 years when age-specific prev-
alence begins to decline. This decline among older age
groups supports the hypothesis that the population aged 30–
50 years was the most affected by the PAT campaign. It
would be valuable to gain prevalence data of the older
population in smaller age group intervals and in different
geographic locations to examine HCV incidence and PAT
trends more closely.
Although the overall prevalence of HCV infection in Egypt
is relatively high, the incidence of new infections needed to
maintain this prevalence is still low enough that it is difficult
to obtain precise incidence estimates. Therefore, results from
our modelling approach should not be used to measure
changes in IRs over time or differences in IRs between risk
groups. Again, this was the principle reason why we chose
to estimate incidence from only one study. While estimates
from multiple studies could have been calculated, it would
have been difficult to tease apart possible violations of
assumptions when attempting to compare results or draw
broader conclusions. True longitudinal incidence studies are
still the best way to identify nuances in incidence trends
across age, time and space.
Future HCV-related morbidity and mortality in Egypt
Our natural history model predicted 127 821 deaths from
decompensated cirrhosis and 117 556 deaths from hepato-
cellular carcinoma due to the HCV epidemic over the next
10–20 years. We also calculated that the infected cohort
would spend 750 210 years in the diseased state of
decompensated cirrhosis, 132 894 years in hepatocellular
carcinoma and lose 32.86 million years of life in comparison
to an age-sex-matched non-infected cohort. These disturbing
projections actually may have underestimated total HCV-
related morbidity and mortality for a few reasons. All cases
of acute hepatitis were excluded, because Egypt does not
have highly accurate data regarding acute infection and its
natural history. Thus, we chose to limit our natural history
model and projections to those with chronic HCV infection.
In addition, the possibility of accelerated progression among
older cases or those co-infected with HBV or HIV was not
considered, cases that may be more likely to develop hepatic
complications [28]. To date there has only been one other
model constructed to look at HCV specifically in Egypt, and it
involved fitting a model to historic data [29]. Although there
was evidence that age- and sex-influenced parameter esti-
mates, confirmatory observational data are not yet presently
available for comparison. Consequently, we elected to work
with a more conservative model, assuring a baseline, or
underestimated, projection of future morbidity and mortal-
ity. We also did not evaluate HBV separately. Just as many
people were infected with HBV as with HCV during the PAT
campaign; however, HBV only caused chronic infections in
5% or less of infected individuals, whereas chronic HCV
infection developed in 70–80% [3,6]. This is related to the
natural history of HBV, where the probability of developing
chronic infection decreases with age [30]. Since most people
who received PAT were older than 10–15 years, they were
at less risk for developing persistent HBV infection [6]. In
addition, the HBV vaccine has been incorporated since
1992, which should lead to a steady decline in the signifi-
cance of HBV infection, eventually playing only a minor role
in the future of liver disease in Egypt.
Our analysis suggested the health burden related to pre-
mature mortality or disability from decompensated cirrhosis
or hepatocellular carcinoma may be very high. The value of
these estimates is that they inform policy makers about the
rates at which age-specific groups are becoming infected
with HCV and what these estimates will mean in terms of
future morbidity and mortality. This information is crucial,
because it can lead to conclusions about the level and
direction of the HCV epidemic in Egypt that might be less
readily apparent from the prevalence data alone. Despite the
remarkable decline in new HCV infections since the end of
the PAT campaign, mortality related to existing cases will
likely continue to increase over the next 10–20 years,
similar to the results of Deuffic-Burban et al. [29]. Hence,
there is an urgent need to address this problem as HCV
infection is frequently asymptomatic until cirrhosis develops,
when treatment is less effective. More research regarding
cost-effectiveness of screening for HCV infection and indi-
cations for treatment is needed to help guide public health
policy in this area. Continued research on the natural his-
tory of HCV and the development of new treatments should
remain top priorities not only for Egypt, but for global health
as well.
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